The medical device industry saw even more consolidation over the past year, as evidenced by Medical Design & Outsourcing‘s newest Big 100 list. It used to be that a company had to have at least $100 million in annual revenue to make it on the list. This time around, No. 100 on the list is […]
Alcon withdraws all CyPass micro-stents, says it will not affect spin-off
Novartis (NYSE:NVS)’s Alcon said this week it is voluntarily withdrawing its CyPass micro-stents from the global market, but that the withdrawal will not affect its planned spin-out. The decision to pull the devices comes off the analysis of five-year post-surgery data from the Compass-XT study of the device, which showed that patients treated with the stent had […]
Novartis to spin out Alcon ophthalmic subsidiary
Novartis (NYSE:NVS) said today that it’s planning to spin its Alcon ophthalmology subsidiary into a publicly traded company after years of speculation that it wanted to sell the ill-starred division. The Swiss pharma giant said it intends to hold on to Alcon’s $4.6 billion ophthalmic pharmaceuticals business under the Novartis Innovative Medicines umbrella, continuing a […]
Alcon launches project to reduce cataract blindness
Alcon, a division of Novartis, launched its Alcon Cares Project 100 to take steps in reducing cataract blindness globally. The company also plans to donate 100 reprocessed Infiniti units to eligible clinics in Asia, Central and South America and Africa over the next three years. Alcon aims to reduce cataract blindness by providing equipment to […]
InVivo Therapeutics lifts Toselli to permanent prez, CEO | Personnel Moves February 6, 2018
InVivo Therapeutics (NSDQ:NVIV) said yesterday it made Dr. Richard Toselli’s spot in the corner office permanent, lifting him from acting CEO to prez and CEO. Dr. Toselli will maintain his position on the company’s board and as its chief medical officer, the position he was given when he joined the company last July. Prior to joining InVivo, […]
7 medtech stories we missed this week: Oct. 13, 2017
From Orthocell’s distribution deal to CorNeat unveiling its artificial cornea, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. OrthoCell inks Australian distro deal Orthocell announced in an Oct. 10 press release that it has signed a distribution deal with Surgical Specialities. The deal will make Surgical Specialities the […]
The 20 largest medical device companies in the world
When it comes to the largest medical device companies, it’s a changing cast of players – as demonstrated once again in Medical Design & Outsourcing’s latest Big 100 list. We pulled financial regulatory filings and reached out to major companies in some cases to create a list of the 100 largest medical device companies in […]
Novartis unit Alcon posts modest Q2 gain
(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today. The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued […]
UPDATE: Potential Alcon sale worries Novartis investors
Updated to include new details of Novartis’ M&A strategy. Novartis (NYSE:NVS) CEO Joe Jimenez’s consideration of the sale of the Alcon subsidiary has investors worried that the influx of cash – Alcon’s surgical devices and contact lens business could fetch as much as $35 billion – will result in another misguided acquisition. The Swiss drugmaker […]
LivaNova snags former J&J exec Huston as CFO | Personnel Moves, May 24, 2017
LivaNova (NSDQ:LIVN) said last week that it picked up former Johnson & Johnson medical device group chief financial officer Thad Huston as its new CFO, effective May 20. Huston will replace former CFO Vivid Sehgal, who coordinated with Huston during the transition. Huston spent more than 25 years with Johnson & Johnson, and held various positions, […]
Glaukos slides on report of increased competition from Alcon
Glaukos (NYSE:GKOS) shares are off some 7% today on a report that increased competition from the Alcon unit of Novartis (NYSE:NVS). The once-high-flying stock could lose 30% of its value this year as Glaukos loses its monopoly on the ocular stent, according to a report today in Barron’s. The San Clemente, Calif.-based company’s iStent, which won FDA […]
- 1
- 2
- 3
- 4
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+